Skip to content

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

PRESS RELEASES

Choose Year
Search Press Releases

Found 215 Results

November 28, 2018

Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain

November 21, 2018

Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018

November 19, 2018

Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers

November 15, 2018

Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018

November 7, 2018

Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018

November 5, 2018

Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates

October 29, 2018

Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018

August 22, 2018

Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)

August 2, 2018

Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates

July 26, 2018

Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018

«...9 101112 13...»

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Minerva Neurosciences, Inc.
1500 District Avenue
Burlington, MA 01803

Company

About Us
Leadership
Board of Directors
Contact

Science

Our Approach
Pipeline
Publications
Clinical Trials

Investors

Investors Overview
News
Events
SEC Filings
Stock Information
Corporate Governance
FAQs

© 2026 Minerva Neurosciences, Inc.

Privacy Policy
Terms of Use
Accessibility Statement
Cookie Policy

Scroll to Top